Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 6

recruiting
3 975
countries
28
conditions
2 109

151 trials match your criteria

Glioblastoma multiforme

Not yet recruiting

Study of autologous mature dendritic cell vaccine plus atezolizumab in patients with recurrent glioblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Hepatocellular carcinoma

Not yet recruiting

Advanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Neoplasm

Not yet recruiting

Study on Pembrolizumab, Atezolizumab, and Nivolumab with Carbon Ion Radiotherapy for Patients with Advanced Melanoma, Urothelial Carcinoma, NSCLC, or Head & Neck Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Breast cancer female

Not yet recruiting

Study of Atezolizumab, Pertuzumab, and Trastuzumab for Patients with HER2 Positive Early High-Risk and Locally Advanced Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Non-small cell lung cancer

Not yet recruiting

Study of Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study of ipatasertib with atezolizumab and chemotherapy in women with triple-negative breast cancer before surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study of Lutetium (177Lu) Oxodotreotide, Carboplatin, Etoposide, and Atezolizumab in Newly Diagnosed Extensive Stage Small Cell Lung Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study on the Effectiveness of NMS-01940153E, Atezolizumab, and Decitabine in Adults with Unresectable Liver Cancer Previously Treated with Other Cancer Medicines

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study on Fecal Microbiota Transplant with Atezolizumab and Bevacizumab for Liver Cancer Patients Unresponsive to Previous Immunotherapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Study of Atezolizumab, Carboplatin, and Paclitaxel for Elderly Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Atezolizumab

Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.